Georgia Yates

MSR45 Bayesian Parametric Mixture Cure Survival Models With Delayed Treatment Effects and Application to Targeted Therapies in Advanced Ovarian Cancer

Daniel Sharpe, Georgia Yates, Ashley E. Tate, Tuli De et autres

gb (code pays fourni par la source)

EE510 Healthcare Resource Utilization Among Adults With Pneumococcal Disease in England 2017-2022: A Retrospective Database Analysis

M. Doyinsola Bailey, John J. Were, Sariga Kakkamani, Rafael Coderch Lanau et autres

us, gb (code pays fourni par la source)

A Bayesian Model Leveraging Multiple External Data Sources to Improve the Reliability of Lifetime Survival Extrapolations in Metastatic Non-Small-Cell Lung Cancer

Daniel Sharpe, Georgia Yates, Mohammad Ashraf Chaudhary, Yong Yuan et autres

ObjectivesBayesian multiparameter evidence synthesis (B-MPES) can improve the reliability of long-term survival extrapolations by leveraging registry data. We extended the B-MPES framework to also incorporate historical trial data and examined the impact of alternative external information sources on predictions from early data …

gb, us (code pays fourni par la source)

Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial

Daniel M. Geynisman, Kateryna Chepynoga, Georgia Yates, Ashley Tate et autres

us, gb (code pays fourni par la source)

EE270 Cost-Effectiveness Evaluation of Sequential Treatment Stategies for Treatment Naïve Patients With BRAF Mutant Metastatic Melanoma in UK: Nivolumab Plus Ipilimumab First-Line Versus Dabrafenib Plus Trametinib First-Line

Adam Tokarz, Rong Sheng Cai, B. Baginska-Dudek, Georgia Yates et autres

pl, gb, in, us, it (code pays fourni par la source)

MSR195 Reducing Uncertainty in Post-Response Survival Estimates Using Bayesian Copula Models Informed by Historical Trial Data

D SHARPE, AE Tate, Georgia Yates, Kateryna Chepynoga et autres

gb, in, us (code pays fourni par la source)

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials

Jeffrey S. Weber, Mark Ross Middleton, Georgia Yates, Daniel Sharpe et autres

PURPOSE: Standard-of-care treatments for patients with resected stage III/IV melanoma include the immuno-oncology (IO) agents nivolumab (NIVO) and ipilimumab (IPI). This study used mixture cure models (MCMs) to estimate cure rates among patients treated with NIVO or IPI in the phase III …

us, gb, de (code pays fourni par la source)

Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer

Martin Reck, Tuli De, Luis G Paz-Ares, Mark Edmondson-Jones et autres

OBJECTIVES: CheckMate 227 (NCT02477826) evaluated first-line nivolumab-plus-ipilimumab versus chemotherapy in patients with metastatic nonsmall cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression ≥ 1% or < 1% and no EGFR/ALK alterations. However, many patients randomized to chemotherapy received subsequent …

de, gb, es, se, be (code pays fourni par la source)

EE395 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Current Standard of Care (SOC) for Patients with Unresectable or Metastatic Melanoma in Canada

ES Mameri, Lisa McDonald, J Villeneuve, Flavia Ejzykowicz et autres

ca, gb, it, se, be, in (code pays fourni par la source)

MSR67 Modelling the Patient-Level Dependence of Overall Survival on Time to Objective Response in Oncology Studies Using Copulas

DJ Sharpe, AE Tate, Georgia Yates, Kateryna Chepynoga et autres

gb, in, us (code pays fourni par la source)

MSR77 Incorporating Cure Effect into Copula Models for Long-Term Survival Projections: A Case Study in Previously Treated Advanced Esophageal Squamous Cell Carcinoma (aESCC)

DJ Sharpe, Georgia Yates, T De, Preet Paul Singh et autres

gb, us (code pays fourni par la source)

Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.

Daniel M. Geynisman, Georgia Yates, Kateryna Chepynoga, S Teitsson et autres

528 Background: Durable DFS and cure are the ultimate goals for the treatment of muscle invasive urothelial carcinoma (MIUC) with radical cystectomy. This analysis employed mixture cure models (MCMs) to estimate the underlying cure fraction among high-risk MIUC patients following radical resection …

us, gb (code pays fourni par la source)